Following a year long downtrend after management followed through with a secondary offering, my chart shows a possible cement floor at 1.80. Higher accumulation and a recent uptrend could mean a lot of upside for the drug development company.
With FDA planning to regulate nicotine levels, XXII (holding 200 patents protecting their production/manufaturing methods for making VLN, very low nicotine, tobacco) is well positioned to capitalize on the ~$20b of Big Tobacco market cap lost since July. In July, the FDA publicly announced their ambitions to change tobacco regulation. In addition, the FDA has...
